Innovent reports Phase 3 survival gains: UBS targets Innovent stock at HKD 135.30

Published on 10/25/2026 at 02:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS set HKD 135.30 on October 19, 2026. Innovent stock saw 10.2 versus 6.9 months of survival in 464 Phase 3 patients.

Clinical data and valuation

Innovent reported 10.2 months of median overall survival versus 6.9 months on October 23, 2026.
UBS set a HKD 135.30 price target on October 19, 2026.
Innovent's market capitalization was HKD 145.1 billion on October 23, 2026.

Innovent, KYG4818G1010, Illustration mit AI erstellt.

Innovent Biologics (ISIN KYG4818G1010) reported positive Phase 3 results on October 23, 2026, while UBS set a HKD 135.30 price target on October 19, 2026. The G-HOPE-001 study delivered median overall survival of 10.2 months versus 6.9 months for physician's choice, according to FT.com and Markets Insider.

Phase 3 data reset the pipeline

The trial met its primary overall-survival and progression-free-survival endpoints in previously treated, CLDN18.2-positive gastric or gastroesophageal junction cancer. Median progression-free survival reached 7.1 months with arcotatug tavatecan, compared with 3.1 months for physician's choice, while the confirmed objective response rate was 37.4 percent versus 7.7 percent, FT.com reported on October 23, 2026.

The study enrolled 464 patients in China and Japan. Grade 3 or higher treatment-related adverse events affected 47.4 percent of patients receiving arcotatug tavatecan versus 55.9 percent in the control group, according to RTTNews. The compound remains investigational, and its China application is under priority review.

What does the target signal mean?

UBS maintained a Buy rating and set a HKD 135.30 target on October 19, 2026. CMB International Securities maintained a Buy rating with a HKD 138.63 target in a report released on October 16, 2026, according to Markets Insider. The targets put the emphasis on regulatory execution after the clinical readout rather than on a single trial statistic.

Three dated milestones

On October 16, 2026, CMB International Securities kept its Buy rating and HKD 138.63 target. On October 19, 2026, UBS set its HKD 135.30 target. On October 23, 2026, Innovent reported the 10.2-month overall-survival result and the 7.1-month progression-free-survival result.

Next dated milestone

The ESMO Congress runs through October 27, 2026, and Takeda plans further global Phase 3 development of arcotatug tavatecan, according to Takeda.

Hong Kong valuation context

Innovent's market capitalization was HKD 145.1 billion on October 23, 2026. The stock's 52-week range was HKD 69.55 to HKD 112.70, leaving the clinical update to be weighed against a valuation that already reflects substantial pipeline expectations.

Innovent's last Hong Kong quote was HKD 83.20 on October 23, 2026 at 4:08 p.m. HKT. The further course of trading is shown by the continuously updated real-time quote of Innovent stock.